Open in Screener

BBIO

BridgeBio Pharma Inc

Oct 07 • 11:37AM ET

53.43

-1.18 -2.16 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI VB IWM VBK XBI VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.09	Insider Own	15.13%	Shs Outstand	191.16M	Perf Week	2.87%
Market Cap	10.21B	Forward P/E	-	EPS next Y	-1.85	Insider Trans	-26.85%	Shs Float	162.24M	Perf Month	-1.58%
Enterprise Value	12.14B	PEG	-	EPS next Q	-0.88	Inst Own	89.29%	Short Float	11.98%	Perf Quarter	16.20%
Income	-776.41M	P/S	43.32	EPS this Y	-22.37%	Inst Trans	7.11%	Short Ratio	7.79	Perf Half Y	74.21%
Sales	235.81M	P/B	-	EPS next Y	47.41%	ROA	-82.84%	Short Interest	19.44M	Perf YTD	94.72%
Book/sh	-9.35	P/C	13.49	EPS next 5Y	83.74%	ROE	-	52W High	54.64 -2.21%	Perf Year	108.47%
Cash/sh	3.96	P/FCF	-	EPS past 3/5Y	9.60% -3.04%	ROIC	-88.26%	52W Low	21.72 145.99%	Perf 3Y	437.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.10% 40.48%	Gross Margin	94.79%	Volatility	3.41% 3.37%	Perf 5Y	42.40%
Dividend TTM	-	EV/Sales	51.50	EPS Y/Y TTM	-55.29%	Oper. Margin	-273.84%	ATR (14)	1.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.08	Sales Y/Y TTM	7.62%	Profit Margin	-329.25%	RSI (14)	56.64	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	5.19	EPS Q/Q	-143.82%	SMA20	2.66%	Beta	1.38	Target Price	67.72
Payout	-	Debt/Eq	-	Sales Q/Q	4999.86%	SMA50	5.88%	Rel Volume	0.71	Prev Close	54.61
Employees	730	LT Debt/Eq	-	Earnings	Aug 05 AMC	SMA200	35.04%	Avg Volume	2.49M	Price	53.43
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.74% 25.66%	Trades		Volume	637,438	Change	-2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-25	Resumed	Raymond James	Outperform	$56
Jul-21-25	Initiated	Truist	Buy	$66
Jul-14-25	Initiated	Jefferies	Buy	$70
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform	$60
Jun-17-25	Initiated	Wolfe Research	Outperform	$49
Mar-31-25	Initiated	Redburn Atlantic	Buy	$50
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	SVB Leerink	Outperform	$66 → $24
Dec-27-21	Reiterated	Mizuho	Buy	$86 → $25

Show Previous Ratings

Oct-03-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 04:55PM	UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch (Insider Monkey)
09:46AM	BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics (Insider Monkey)
Oct-01-25 06:58PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
11:05AM	Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? (Zacks)
04:24PM	Loading…
Sep-29-25 04:24PM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
10:42AM	BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition (Benzinga)
Sep-28-25 11:20AM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
11:15AM	Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM (GlobeNewswire)
Sep-24-25 02:12AM	H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) (Insider Monkey)
01:58AM	BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism (Insider Monkey)
Sep-22-25 07:30AM	BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 (GlobeNewswire)
Sep-10-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-25 10:15AM	Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? (Zacks)
Sep-06-25 02:30PM	Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism (GlobeNewswire)
07:00PM	Loading…
Sep-05-25 07:00PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Sep-03-25 07:30AM	BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET (GlobeNewswire)
Sep-02-25 07:03PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:30AM	BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Aug-30-25 07:15AM	Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension (GlobeNewswire)
Aug-28-25 11:49PM	Here's What Wall Street Thinks About BridgeBio Pharma (BBIO) (Insider Monkey) +6.01%
06:48PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
10:10AM	Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? (Zacks)
Aug-27-25 07:30AM	BridgeBio to Participate in September Investor Conferences (GlobeNewswire)
Aug-25-25 07:30AM	BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 (GlobeNewswire)
Aug-20-25 12:34AM	TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales (Insider Monkey)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
Aug-06-25 02:18PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -8.94%
07:33AM	Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics (GlobeNewswire)
07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
03:29AM	Loading…
03:29AM	BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... (GuruFocus.com)
Aug-05-25 05:25PM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:26PM	BridgeBio Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-04-25 09:22AM	BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-30-25 12:37PM	Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. (Barrons.com)
09:40AM	Peloton upgraded, Booking downgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:00AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-25-25 11:29PM	Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT (Insider Monkey)
Jul-24-25 11:47PM	Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy (Insider Monkey)
Jul-23-25 07:30AM	Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 (GlobeNewswire)
Jul-22-25 07:30AM	BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET (GlobeNewswire)
Jul-16-25 06:17AM	These 2 Momentum Stocks Got a Bullish Nod Heres Why They Could Reach New Highs (TipRanks)
Jul-14-25 09:32AM	Rivian downgraded, PayPal upgraded: Wall Street's top analyst calls (The Fly)
Jul-09-25 09:39AM	Microsoft upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly) +6.46%
Jul-06-25 04:00AM	BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA (Insider Monkey)
Jul-02-25 10:29AM	BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights (Insider Monkey)
Jun-30-25 07:30AM	BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty (GlobeNewswire)
Jun-26-25 07:30AM	BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET (GlobeNewswire)
Jun-25-25 06:01AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks That Are Ticking Every Box (TipRanks)
Jun-24-25 04:25AM	Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results (Insider Monkey) +5.39%
Jun-11-25 07:54PM	BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright (Insider Monkey)
Jun-05-25 08:50AM	BridgeBio price target raised to $42 from $37 at BMO Capital (TipRanks)
Jun-02-25 07:30AM	BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire)
May-23-25 03:21PM	Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
04:24AM	BridgeBio's Acoramidis: A Breakthrough in ATTR-CM Treatment (Insider Monkey)
May-20-25 09:40AM	Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year? (Zacks)
07:30AM	Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM (GlobeNewswire)
May-19-25 12:33PM	Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study (GlobeNewswire)
May-14-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:27AM	BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug (Clinical Trials Arena)
06:50AM	Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday (Insider Monkey)
May-13-25 09:55AM	Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade (Zacks) -6.78%
07:30AM	First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study (GlobeNewswire)
May-12-25 07:30AM	BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC (GlobeNewswire)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
07:30AM	BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 (GlobeNewswire)
Apr-30-25 09:12PM	Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday (Insider Monkey) +5.33%
04:27PM	BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations (Investor's Business Daily)
12:31PM	Q1 2025 BridgeBio Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
10:04AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:07AM	BridgeBio sales of new heart drug outstrip expectations (BioPharma Dive)
03:17AM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Apr-29-25 09:43PM	BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	BridgeBio Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations (Investor's Business Daily)
04:01PM	BridgeBio Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
11:39AM	BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
10:29AM	UK MHRA authorises BridgeBios acoramidis for ATTR-CM (Pharmaceutical Technology)
Apr-28-25 07:18PM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
05:00AM	BEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM (GlobeNewswire)
Apr-23-25 10:01AM	Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-22-25 11:14AM	BridgeBio: Early Signs Point To Blockbuster Revenues (Seeking Alpha)
07:30AM	BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET (GlobeNewswire)
Apr-11-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-31-25 10:00AM	Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM (GlobeNewswire)
Mar-29-25 04:12PM	Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 07:00AM	Beyonttra (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved in Japan to Treat ATTR-CM (GlobeNewswire)
Mar-24-25 07:30AM	BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions (GlobeNewswire) +7.05%
Mar-21-25 05:37PM	Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (SeekingAlpha)
04:13PM	Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio (Investor's Business Daily)
04:00PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:04PM	Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug (Pharmaceutical Technology)
01:21PM	Alnylam Stock Jumps After the FDA Approves Its Heart Drug (The Wall Street Journal)
10:05AM	Alnylam Heart Drug Approval Sets Up Challenge With Pfizer (Bloomberg)
Mar-20-25 06:13PM	Alnylam nabs key additional indication for Amvuttra (SeekingAlpha)
Mar-17-25 04:01PM	BridgeBio Announces CFO Succession (GlobeNewswire)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCCORMICK FRANK	Director	Sep 05 '25	Option Exercise	11.92	74,000	882,080	157,275	Sep 08 06:06 PM
MCCORMICK FRANK	Director	Sep 05 '25	Sale	53.16	74,000	3,933,544	83,275	Sep 08 06:06 PM
Kumar Neil	Chief Executive Officer	Sep 05 '25	Sale	53.05	40,000	2,122,047	875,686	Sep 08 06:05 PM
Kumar Neil	Chief Executive Officer	Sep 04 '25	Sale	51.34	40,000	2,053,788	895,686	Sep 08 06:05 PM
FRANK P. MCCORMICK	Director	Sep 05 '25	Proposed Sale	53.14	74,000	3,932,057		Sep 05 04:46 PM
Trimarchi Thomas	President and CFO	Aug 21 '25	Sale	49.48	42,237	2,090,081	421,081	Aug 22 04:58 PM
Kumar Neil	Chief Executive Officer	Aug 20 '25	Sale	48.82	26,156	1,276,927	223,090	Aug 22 04:46 PM
THOMAS TRIMARCHI	Officer	Aug 21 '25	Proposed Sale	49.48	42,237	2,090,077		Aug 21 04:10 PM
NEIL KUMAR	Director	Aug 20 '25	Proposed Sale	48.91	26,156	1,279,290		Aug 20 04:23 PM
Trimarchi Thomas	President and CFO	Aug 18 '25	Sale	50.23	17,353	871,722	463,318	Aug 19 07:40 PM
THOMAS TRIMARCHI	Officer	Aug 18 '25	Proposed Sale	50.23	17,353	871,723		Aug 18 04:03 PM
HOMCY CHARLES J	Director	Aug 08 '25	Sale	46.05	250,000	11,512,443	966,674	Aug 12 07:06 PM
HOMCY CHARLES J	Director	Aug 11 '25	Sale	48.00	50,000	2,400,000	916,674	Aug 12 07:06 PM
Apuli Maricel	Chief Accounting Officer	Aug 07 '25	Sale	45.44	1,000	45,440	141,859	Aug 11 06:29 PM
Kumar Neil	Chief Executive Officer	Aug 08 '25	Sale	46.22	40,000	1,848,828	915,686	Aug 11 06:12 PM
Kumar Neil	Chief Executive Officer	Aug 07 '25	Sale	45.45	40,000	1,818,121	935,686	Aug 11 06:12 PM
CHARLES J HOMCY	Director	Aug 11 '25	Proposed Sale	48.00	50,000	2,400,000		Aug 11 04:17 PM
CHARLES J HOMCY	Director	Aug 08 '25	Proposed Sale	46.05	250,000	11,512,420		Aug 08 05:11 PM
Ellis Andrea	Director	Aug 05 '25	Option Exercise	16.75	17,167	287,547	35,756	Aug 07 04:50 PM
Ellis Andrea	Director	Aug 05 '25	Sale	49.00	17,167	841,183	18,589	Aug 07 04:50 PM
ANDREA ELLIS	Director	Aug 05 '25	Proposed Sale	49.00	17,167	841,183		Aug 05 04:26 PM
Kumar Neil	Chief Executive Officer	Jul 02 '25	Sale	42.73	40,000	1,709,050	955,686	Jul 03 04:30 PM
Kumar Neil	Chief Executive Officer	Jul 01 '25	Sale	42.54	40,000	1,701,400	975,686	Jul 03 04:30 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jun 27 '25	Sale	44.00	3,500,000	154,000,000	18,555,375	Jul 01 07:48 PM
KUMAR HALDEA REVOCABLETRUST U/	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,418	106,504	7,465	Jun 30 05:51 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,289	100,824	398	Jun 30 05:51 PM
MCCORMICK FRANK	Director	Jun 24 '25	Sale	44.23	100,000	4,422,800	879,979	Jun 26 05:08 PM
DENIS VON KAEPPLER IRA ROLLOVE	client's wife is a BoD	Jun 26 '25	Proposed Sale	44.03	1,891	83,261		Jun 26 04:19 PM
HANNAH VALANTINE & DENIS VON K	spouse of bod / bod is joint o	Jun 26 '25	Proposed Sale	44.01	1,542	67,863		Jun 26 04:16 PM
HANNAH A VALANTINE & DENIS VON	Officer	Jun 26 '25	Proposed Sale	44.11	876	38,640		Jun 26 04:14 PM
ERICKA VON KAEPPLER & DENIS VO	account owners are spouse and	Jun 26 '25	Proposed Sale	44.13	398	17,562		Jun 26 04:13 PM
MCCORMICK FRANK	Officer	Jun 24 '25	Proposed Sale	44.23	100,000	4,422,803		Jun 24 05:59 PM
Valantine Hannah	Director	Jun 10 '25	Option Exercise	16.75	4,292	71,891	6,056	Jun 11 05:00 PM
Valantine Hannah	Director	Jun 10 '25	Sale	40.00	4,292	171,680	1,764	Jun 11 05:00 PM
HANNAH A VALANTINE	Director	Jun 10 '25	Proposed Sale	40.00	4,292	171,680		Jun 10 04:01 PM
Kumar Neil	Chief Executive Officer	May 20 '25	Sale	33.40	75,000	2,504,978	4,798,447	May 20 06:06 PM
Kumar Neil	Chief Executive Officer	May 19 '25	Sale	33.33	26,156	871,764	217,404	May 20 06:06 PM
NEIL KUMAR	Director	May 19 '25	Proposed Sale	33.84	26,156	885,119		May 19 04:25 PM
KKR Genetic Disorder L.P.	10% Owner	May 12 '25	Sale	34.20	6,000,000	205,200,000	13,260,971	May 14 05:24 PM
KKR Genetic Disorder L.P.	Affiliate	May 12 '25	Proposed Sale	35.68	6,000,000	214,080,000		May 12 09:46 PM
Apuli Maricel	Chief Accounting Officer	May 02 '25	Sale	38.51	1,026	39,509	147,639	May 06 04:45 PM
Lo Andrew	Director	May 02 '25	Sale	38.50	100,000	3,849,900	105,583	May 06 04:42 PM
Lo Andrew	Director	May 02 '25	Proposed Sale	35.23	100,000	3,523,000		May 02 04:36 PM
Kumar Neil	Chief Executive Officer	Apr 22 '25	Sale	34.11	75,000	2,558,025	4,873,447	Apr 24 04:28 PM
Ellis Andrea	Director	Apr 14 '25	Option Exercise	8.45	10,000	84,500	22,000	Apr 16 05:39 PM
Ellis Andrea	Director	Apr 14 '25	Sale	35.00	10,000	350,000	12,000	Apr 16 05:39 PM
ANDREA ELLIS	Director	Apr 14 '25	Proposed Sale	35.00	10,000	350,000		Apr 14 04:21 PM
Ellis Andrea	Director	Apr 01 '25	Option Exercise	8.45	30,000	253,500	42,000	Apr 03 05:11 PM
Ellis Andrea	Director	Apr 01 '25	Sale	34.05	30,000	1,021,500	12,000	Apr 03 05:11 PM
ANDREA ELLIS	Director	Apr 01 '25	Proposed Sale	34.05	30,000	1,021,500		Apr 02 04:48 PM
Kumar Neil	Chief Executive Officer	Mar 25 '25	Sale	36.87	75,000	2,764,943	4,948,447	Mar 27 04:54 PM
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM
BRIAN STEPHENSON	Officer	Feb 25 '25	Proposed Sale	36.25	34,000	1,232,500		Feb 25 04:34 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Feb 19 '25	Sale	36.16	4,148	149,973	102,464	Feb 19 08:50 PM
Kumar Neil	Chief Executive Officer	Feb 19 '25	Sale	36.14	31,543	1,140,024	211,718	Feb 19 08:48 PM
NEIL KUMAR	Director	Feb 19 '25	Proposed Sale	35.49	31,543	1,119,461		Feb 19 04:31 PM
BRIAN STEPHENSON	Officer	Feb 19 '25	Proposed Sale	35.49	4,148	147,213		Feb 19 04:31 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Proposed Sale	34.90	3,065,616	106,989,998		Jan 31 07:18 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Sale	34.90	3,065,616	106,989,998	22,055,375	Jan 31 07:18 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Option Exercise	17.00	68,000	1,156,000	161,758	Jan 30 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Sale	36.29	68,000	2,467,761	93,758	Jan 30 06:31 PM
Kumar Neil	Chief Executive Officer	Jan 28 '25	Sale	36.29	326,932	11,863,381	5,371,515	Jan 30 06:29 PM
Kumar Neil	Chief Executive Officer	Jan 29 '25	Sale	36.35	273,068	9,925,269	5,098,447	Jan 30 06:29 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 28 '25	Proposed Sale	36.67	600,000	22,002,000		Jan 28 04:18 PM
BRIAN STEPHENSON	Officer	Jan 28 '25	Proposed Sale	36.67	68,000	2,493,560		Jan 28 04:18 PM
Satvat Ali J.	Director	Dec 30 '24	Option Exercise	16.22	159,404	2,585,134	159,404	Dec 31 05:52 PM
Kumar Neil	Chief Executive Officer	Nov 19 '24	Sale	22.41	27,389	613,826	4,897,443	Nov 20 08:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Nov 19 '24	Sale	22.41	4,156	93,137	93,758	Nov 20 07:57 PM
BRIAN STEPHENSON	Officer	Nov 19 '24	Proposed Sale	22.35	4,156	92,887		Nov 19 04:28 PM
NEIL KUMAR	Director	Nov 19 '24	Proposed Sale	22.35	27,389	612,144		Nov 19 04:24 PM

Open in Screener

APG

APi Group Corporation

Oct 07 • 11:37AM ET

34.44

-0.52 -1.50 %

Industrials • Engineering & Construction • USA • NYSE

APG APi Group Corporation daily Stock Chart

Peers: J ACM PWR FLR AGX DY FIX PRIM TPC VSEC

| Held by: VTI IJH VB VBR VXF MDY XMMO SPMD IWR IJK

Index	-	P/E	102.98	EPS (ttm)	0.33	Insider Own	16.49%	Shs Outstand	415.32M	Perf Week	0.19%
Market Cap	14.46B	Forward P/E	20.72	EPS next Y	1.66	Insider Trans	-3.08%	Shs Float	350.64M	Perf Month	-2.15%
Enterprise Value	17.09B	PEG	7.19	EPS next Q	0.39	Inst Own	83.68%	Short Float	2.94%	Perf Quarter	-0.16%
Income	141.00M	P/S	1.95	EPS this Y	18.42%	Inst Trans	0.02%	Short Ratio	3.93	Perf Half Y	59.72%
Sales	7.40B	P/B	4.58	EPS next Y	14.41%	ROA	3.01%	Short Interest	10.30M	Perf YTD	43.60%
Book/sh	7.53	P/C	33.47	EPS next 5Y	14.33%	ROE	8.26%	52W High	36.55 -5.79%	Perf Year	64.03%
Cash/sh	1.03	P/FCF	25.41	EPS past 3/5Y	-7.92% -16.79%	ROIC	2.30%	52W Low	20.50 67.95%	Perf 3Y	289.24%
Dividend Est.	-	EV/EBITDA	20.61	Sales past 3/5Y	21.22% 11.39%	Gross Margin	28.03%	Volatility	1.38% 1.79%	Perf 5Y	262.98%
Dividend TTM	-	EV/Sales	2.31	EPS Y/Y TTM	125.65%	Oper. Margin	6.90%	ATR (14)	0.63	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.37	Sales Y/Y TTM	7.59%	Profit Margin	1.91%	RSI (14)	46.44	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	1.45	EPS Q/Q	-3.30%	SMA20	-0.80%	Beta	1.64	Target Price	41.30
Payout	-	Debt/Eq	0.96	Sales Q/Q	15.03%	SMA50	-1.74%	Rel Volume	0.27	Prev Close	34.96
Employees	29000	LT Debt/Eq	0.93	Earnings	Jul 31 BMO	SMA200	16.64%	Avg Volume	2.62M	Price	34.44
IPO	Oct 05, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.25% 4.88%	Trades		Volume	254,783	Change	-1.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-25	Upgrade	JP Morgan	Neutral → Overweight	$42
Jun-24-25	Resumed	JP Morgan	Neutral	$46
Jan-22-25	Initiated	Truist	Buy	$45
Jan-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$45
Dec-05-24	Initiated	William Blair	Outperform
Mar-15-24	Initiated	Jefferies	Buy	$48
Jan-25-24	Resumed	UBS	Buy	$40
May-17-23	Upgrade	Robert W. Baird	Neutral → Outperform	$27 → $29
Jul-11-22	Upgrade	BofA Securities	Neutral → Buy	$23
Jun-17-22	Initiated	JP Morgan	Neutral	$17
Mar-25-22	Initiated	RBC Capital Mkts	Sector Perform	$24
Mar-22-22	Initiated	BofA Securities	Neutral	$23
Jan-10-22	Downgrade	Robert W. Baird	Outperform → Neutral	$26
Dec-21-21	Resumed	Citigroup	Buy	$28
Sep-22-20	Initiated	Barclays	Overweight	$19
Jun-24-20	Initiated	Robert W. Baird	Outperform	$16
May-27-20	Initiated	UBS	Buy	$13

Show Previous Ratings

Sep-29-25 11:45AM	Acuity Brands Gears Up for Q4 Earnings: Things to Keep in Mind (Zacks)
Sep-15-25 11:35PM	Construction and Maintenance Services Stocks Q2 In Review: APi (NYSE:APG) Vs Peers (StockStory)
Sep-10-25 12:56PM	WU and dLocal Drive Digital Remittance Expansion in Latin America (Zacks)
Sep-01-25 09:40AM	Are Business Services Stocks Lagging APi Group (APG) This Year? (Zacks)
Aug-28-25 12:38AM	3 Profitable Stocks with Open Questions (StockStory)
12:32PM	Loading…
Aug-22-25 12:32PM	Jacobs Secures Landmark Project to Upgrade New York Roads & Bridges (Zacks)
Aug-21-25 05:40AM	3 Industrials Stocks We Keep Off Our Radar (StockStory)
Aug-20-25 07:30AM	APi Group Announces Upcoming Participation in Jefferies Industrial Conference (Business Wire)
Aug-19-25 08:52AM	Are Options Traders Betting on a Big Move in APi Stock? (Zacks)
Aug-18-25 12:45PM	APi (APG) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Aug-15-25 09:40AM	Is APi Group (APG) Stock Outpacing Its Business Services Peers This Year? (Zacks)
Aug-14-25 05:52AM	3 Mid-Cap Stocks That Concern Us (StockStory)
Aug-13-25 12:46PM	Jacobs Secures Program Role in Pediatric Megaproject, Stock Up (Zacks)
12:00PM	All You Need to Know About APi (APG) Rating Upgrade to Strong Buy (Zacks)
10:00AM	Best Momentum Stocks to Buy for August 13th (Zacks)
07:47AM	Loading…
07:47AM	Is it Now A Great Time to Invest in APi Group (APG)? (Insider Monkey)
Aug-12-25 11:14PM	APG Q2 Deep Dive: Organic Growth, M&A Momentum, and Strong Backlog Fuel Outlook (StockStory)
11:09PM	APi's Q2 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Aug-08-25 10:00AM	Best Momentum Stock to Buy for August 8th (Zacks)
Aug-06-25 12:58PM	Global Payments Q2 Earnings Beat on Issuer Solutions Strength (Zacks)
Aug-04-25 07:52AM	APi Group (APG) Investment: A Success in Safety and Growth (Insider Monkey)
Aug-01-25 12:45PM	3 Reasons Growth Investors Will Love APi (APG) (Zacks)
09:27AM	Zacks Industry Outlook Highlights APi, Aramark and Mitie (Zacks)
03:18AM	APi Group Corp (APG) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... (GuruFocus.com)
Jul-31-25 01:23PM	3 Business Services Stocks to Watch in a Prospering Industry (Zacks)
09:57AM	APi (NYSE:APG) Surprises With Strong Q2, Stock Soars (StockStory)
09:30AM	APi (APG) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:45AM	APi (APG) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:41AM	APi: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	APi Group Reports Second Quarter 2025 Financial Results and Raises Full-Year 2025 Outlook (Business Wire)
11:26AM	Loading…
Jul-30-25 11:26AM	Visa Q3 Earnings Beat Estimates on Strong Cross-Border Volumes (Zacks)
11:02AM	Western Union Down 4% on Q2 Earnings Miss & Lowered Outlook (Zacks)
10:34AM	Kyndryl Set to Report Q1 Earnings: What's in the Offing? (Zacks)
09:40AM	Is APi Group (APG) Outperforming Other Business Services Stocks This Year? (Zacks)
09:23AM	APi Group Corp (APG) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-29-25 11:08PM	APi Earnings: What To Look For From APG (StockStory)
12:43PM	Aurora Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
10:22AM	Aptiv Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-28-25 11:01AM	FIX Delivers Robust EPS Growth: What's Driving the Margin Upside? (Zacks)
09:55AM	S&P Global to Report Q2 Earnings: Here's What You Should Know (Zacks)
Jul-25-25 11:58AM	Verisk Set to Report Q2 Earnings: Here's What You Should Know (Zacks)
11:02AM	TT Gears Up to Report Q2 Earnings: Here's What You Should Know (Zacks)
Jul-24-25 11:45AM	Republic Services to Report Q2 Earnings: What's in the Offing? (Zacks)
10:00AM	APi (APG) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-23-25 11:13AM	ManpowerGroup Stock Improves 5% Since Q2 Earnings Beat (Zacks)
11:06AM	Veralto Gears Up to Report Q2 Earnings: Here's What You Should Know (Zacks)
06:05AM	These 2 Momentum Stocks Are Gaining Steam Heres Why Big Banks Say Theyre Headed Higher (TipRanks)
Jul-22-25 02:06PM	Why APi (APG) Shares Are Trading Lower Today (StockStory)
Jul-18-25 12:22PM	Clear Secure Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
09:36AM	Omnicom Group Stock Barely Moves Since Q2 Earnings Beat (Zacks)
Jul-17-25 12:00PM	Here's Why APi (APG) is a Great Momentum Stock to Buy (Zacks)
10:55AM	Equifax Gears Up to Report Q2 Earnings: What's in the Offing? (Zacks)
07:30AM	APi Group Confirms Date of Second Quarter 2025 Earnings Release (Business Wire)
Jul-14-25 12:45PM	Here is Why Growth Investors Should Buy APi (APG) Now (Zacks)
09:40AM	Are Business Services Stocks Lagging Alithya Group (ALYAF) This Year? (Zacks)
Jul-09-25 12:10PM	Will APi (APG) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jun-26-25 12:45PM	Looking for a Growth Stock? 3 Reasons Why APi (APG) is a Solid Choice (Zacks)
12:00PM	APi (APG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Are Business Services Stocks Lagging APi Group (APG) This Year? (Zacks)
12:02AM	APi (APG): Buy, Sell, or Hold Post Q1 Earnings? (StockStory)
Jun-25-25 04:21PM	Do Options Traders Know Something About APi Group Stock We Don't? (Zacks)
Jun-23-25 12:40AM	2 Industrials Stocks to Own for Decades and 1 to Approach with Caution (StockStory)
Jun-20-25 09:49AM	S&P 400 Effect: Index Swaps U.S. Steel For Stock Going Vertical (Investor's Business Daily)
Jun-18-25 05:46PM	APi Group Set to Join S&P MidCap 400 (PR Newswire)
Jun-11-25 02:32PM	Allegion Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
12:33AM	1 Stock Under $50 on Our Watchlist and 2 to Steer Clear Of (StockStory)
Jun-02-25 11:34PM	Construction and Maintenance Services Stocks Q1 In Review: APi (NYSE:APG) Vs Peers (StockStory)
May-29-25 07:30AM	APi Group Announces Upcoming Participation in Baird's 2025 Global Consumer, Technology & Services Conference and the William Blair 45th Annual Growth Stock Conference (Business Wire)
May-28-25 09:40AM	Is APi Group (APG) Stock Outpacing Its Business Services Peers This Year? (Zacks)
May-27-25 02:08PM	Visa Expands Click to Pay Across Asia Pacific Via Hong Kong's ZA Bank (Zacks)
May-21-25 08:55AM	NYSE Content Advisory: Pre-Market update + Retailers report earnings (PR Newswire)
08:55AM	APi Group Announces New Long-Term Financial Targets (Business Wire)
May-09-25 10:12AM	Zacks Industry Outlook Highlights Cintas, APi Group and Bright Horizons Family Solutions (Zacks)
May-08-25 01:59PM	3 Business Services Stocks to Watch in a Prospering Industry (Zacks)
May-07-25 12:00PM	APi (APG) Is Up 13.03% in One Week: What You Should Know (Zacks)
07:30AM	APi Group to Webcast 2025 Investor Day Live on May 21, 2025 (Business Wire)
May-01-25 03:10PM	APi Group Corporation (APG) Q1 2025 Earnings Call Transcript (Seeking Alpha) +6.63%
09:30AM	APi (APG) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:45AM	APi (APG) Q1 Earnings and Revenues Beat Estimates (Zacks)
07:30AM	APi Group Reports First Quarter 2025 Financial Results (Business Wire)
Apr-30-25 02:39AM	Is APi Group (APG) A Small-Cap Construction and Materials Stock Hedge Funds Are Buying? (Insider Monkey)
Apr-25-25 03:07PM	APi Group Stock Sees Improved Relative Price Strength (Investor's Business Daily)
Apr-17-25 07:30AM	APi Group Confirms Date of First Quarter 2025 Earnings Release (Business Wire)
Apr-16-25 12:40AM	Maran Capital Management Q4 2024 Letter (Seeking Alpha)
Apr-02-25 05:06AM	Spotting Winners: APi (NYSE:APG) And Construction and Maintenance Services Stocks In Q4 (StockStory)
Mar-31-25 07:30AM	APi Group Appoints David Jackola Executive Vice President & Chief Financial Officer (Business Wire)
Mar-27-25 09:58AM	Do Options Traders Know Something APi Group (APG) Stock We Don't? (Zacks)
Mar-25-25 05:05AM	3 Reasons APG is Risky and 1 Stock to Buy Instead (StockStory)
Mar-07-25 07:30AM	APi Group Announces Participation in the 2025 J.P. Morgan Industrials Conference (Business Wire)
Feb-26-25 07:30AM	APi Group Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-19-25 07:30AM	APi Group Provides Update on 2024 Performance and Initial 2025 Guidance and Announces Repricing of Term Loan (Business Wire) +7.77%
Feb-05-25 07:30AM	APi Group Confirms Date of Fourth Quarter 2024 Earnings Release and Announces Participation in Upcoming Investor Conferences (Business Wire)
Dec-21-24 08:46AM	APi Group Corporation (APG): A Bull Case Theory (Insider Monkey)
Dec-17-24 07:30AM	APi Group Announces May 2025 Investor Update Meeting and Reiterates FY 2024 Guidance (Business Wire)
Dec-11-24 12:34AM	Why Is APi Group Corp. (APG) Among Halvorsen's Top Stock Picks Right Now? (Insider Monkey)
Nov-26-24 07:30AM	APi Group Announces Participation in the UBS Global Industrials and Transportation Conference (Business Wire)
Nov-22-24 07:30AM	APi Group Announces CFO Transition (Business Wire)
Nov-20-24 03:43PM	Building Industry Partners Announces Strategic Sale of Rapidly Growing Endeavor Fire Protection to APi Group Corporation (Business Wire)
Nov-17-24 04:59PM	APi Group Corporation (APG): A Bull Case Theory (Insider Monkey)
Oct-31-24 09:20AM	APi Group Q3 Adj. EPS Meets Estimates, But Net Sales Miss; Trims FY24 Revenue Outlook (RTT News)

APi Group Corp. engages in the provision of life safety and specialty services. It operates through the Safety Services and Specialty Services segments. The Safety Services segments offers safety services in North America and Europe, focusing on end-to-end integrated occupancy systems (fire protection solutions, HVAC, and entry systems), including design, installation, inspection, and service of these integrated systems. The Specialty Services segment refers to infrastructure services and specialized industrial plant services, which include maintenance and repair of critical infrastructure such as electric, gas, water, sewer, and telecommunications infrastructure. The company was founded by Ashken Ian Guy Handley, Lillie James E and Franklin Martin E in 1926 and is headquartered in New Brighton, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRANKLIN MARTIN E	Director	Sep 02 '25	Sale	34.64	1,200,000	41,568,000	19,868,790	Sep 04 05:03 PM
MEF Holdings, LLLP	Shareholder	Sep 02 '25	Proposed Sale	34.64	1,200,000	41,567,615		Sep 02 07:15 PM
LILLIE JAMES E	Director	Aug 11 '25	Sale	34.88	190,000	6,627,200	7,443,101	Aug 13 05:19 PM
LILLIE JAMES E	Director	Aug 12 '25	Sale	35.23	95,000	3,346,850	7,348,101	Aug 13 05:19 PM
LILLIE JAMES E	Director	Aug 11 '25	Sale	34.88	50,000	1,744,000	1,450,019	Aug 13 05:19 PM
LILLIE JAMES E	Director	Aug 12 '25	Sale	35.23	25,000	880,750	1,425,019	Aug 13 05:19 PM
ASHKEN IAN G H	Director	Aug 12 '25	Sale	35.24	205,550	7,243,582	7,968,167	Aug 13 05:19 PM
ASHKEN IAN G H	Director	Aug 11 '25	Sale	35.01	19,450	680,944	8,398,703	Aug 13 05:19 PM
Ian G. H. Ashken	Director	Aug 11 '25	Proposed Sale	34.46	150,000	5,169,000		Aug 11 05:51 PM
James E. Lillie	Director	Aug 11 '25	Proposed Sale	34.46	250,000	8,615,000		Aug 11 05:18 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Aug 04 '25	Sale	35.38	4,843	171,345	12,116	Aug 05 05:33 PM
Lambert Louis	SVP, Gen Counsel & Secretary	Aug 02 '25	Option Exercise	0.00	16,769	0	17,770	Aug 05 05:33 PM
ARSENIADIS JAMES	Officer	Aug 04 '25	Proposed Sale	35.38	4,843	171,345		Aug 04 04:03 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Jun 22 '25	Option Exercise	0.00	4,662	0	13,144	Jun 24 04:55 PM
ASHKEN IAN G H	Director	Jun 14 '25	Option Exercise	0.00	3,810	0	3,810	Jun 17 05:49 PM
ASHKEN IAN G H	Director	May 05 '25	Sale	42.72	150,000	6,408,000	5,612,102	May 07 05:58 PM
LILLIE JAMES E	Director	May 05 '25	Sale	42.73	200,000	8,546,000	5,088,734	May 07 05:58 PM
LILLIE JAMES E	Director	May 05 '25	Sale	42.73	50,000	2,136,500	996,203	May 07 05:58 PM
Lambert Louis	SVP, Gen Counsel & Secretary	May 02 '25	Sale	41.23	7,096	292,568	340	May 06 04:27 PM
Lambert Louis	Officer	May 02 '25	Proposed Sale	41.23	7,096	292,568		May 02 05:18 PM
JACKOLA GLENN DAVID	Interim CFO	Mar 09 '25	Option Exercise	0.00	5,217	0	11,025	Mar 11 04:19 PM
Becker Russell A.	President and CEO	Mar 09 '25	Option Exercise	0.00	160,951	0	1,558,414	Mar 11 04:19 PM
MORTON KRISTINA M	SVP and Chief People Officer	Mar 09 '25	Option Exercise	0.00	25,678	0	63,589	Mar 11 04:19 PM
LILLIE JAMES E	Director	Mar 03 '25	Sale	37.97	200,000	7,593,433	5,288,734	Mar 05 05:42 PM
LILLIE JAMES E	Director	Mar 03 '25	Sale	37.97	50,000	1,898,359	1,046,203	Mar 05 05:42 PM
ASHKEN IAN G H	Director	Mar 03 '25	Sale	37.84	200,000	7,568,795	5,762,102	Mar 05 05:42 PM
James E. Lillie	Director	Mar 03 '25	Proposed Sale	39.23	500,000	19,615,000		Mar 03 05:22 PM
Ian G. H. Ashken	Director	Mar 03 '25	Proposed Sale	39.23	350,000	13,730,500		Mar 03 05:20 PM
Becker Russell A.	President and CEO	Mar 01 '25	Option Exercise	0.00	22,297	0	1,408,434	Mar 03 05:04 PM
Becker Russell A.	President and CEO	Feb 27 '25	Option Exercise	0.00	32,451	0	1,402,103	Mar 03 05:04 PM
Lambert Louis	SVP, Gen Counsel & Secretary	Mar 01 '25	Option Exercise	0.00	3,586	0	9,201	Mar 03 05:04 PM
Lambert Louis	SVP, Gen Counsel & Secretary	Feb 27 '25	Option Exercise	0.00	4,982	0	8,174	Mar 03 05:04 PM
MORTON KRISTINA M	SVP and Chief People Officer	Mar 01 '25	Option Exercise	0.00	2,945	0	39,302	Mar 03 05:04 PM
MORTON KRISTINA M	SVP and Chief People Officer	Feb 27 '25	Option Exercise	0.00	4,057	0	38,383	Mar 03 05:04 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Mar 01 '25	Option Exercise	0.00	559	0	8,767	Mar 03 05:03 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Feb 27 '25	Option Exercise	0.00	854	0	8,643	Mar 03 05:03 PM
JACKOLA GLENN DAVID	Interim CFO	Mar 01 '25	Option Exercise	0.00	932	0	6,215	Mar 03 05:03 PM
JACKOLA GLENN DAVID	Interim CFO	Feb 27 '25	Option Exercise	0.00	1,423	0	5,904	Mar 03 05:03 PM
Becker Russell A.	President and CEO	Feb 24 '25	Option Exercise	0.00	207,994	0	1,471,980	Feb 26 04:35 PM
JACKOLA GLENN DAVID	Interim CFO	Feb 24 '25	Option Exercise	0.00	5,900	0	7,172	Feb 26 04:34 PM
ASHKEN IAN G H	Director	Nov 13 '24	Sale	36.87	53,868	1,986,113	5,478,779	Nov 14 07:17 PM
LILLIE JAMES E	Director	Nov 13 '24	Sale	36.88	47,939	1,767,990	5,005,411	Nov 14 07:16 PM
LILLIE JAMES E	Director	Nov 13 '24	Sale	36.88	11,985	442,007	1,096,203	Nov 14 07:16 PM
LILLIE JAMES E	Director	Nov 12 '24	Sale	36.74	105,789	3,886,347	5,053,350	Nov 13 06:51 PM
LILLIE JAMES E	Director	Nov 11 '24	Sale	36.98	46,272	1,711,139	5,159,139	Nov 13 06:51 PM
LILLIE JAMES E	Director	Nov 12 '24	Sale	36.74	26,447	971,578	1,108,188	Nov 13 06:51 PM
LILLIE JAMES E	Director	Nov 11 '24	Sale	36.98	11,568	427,785	1,134,635	Nov 13 06:51 PM
ASHKEN IAN G H	Director	Nov 12 '24	Sale	36.73	99,675	3,660,576	5,532,647	Nov 13 06:50 PM
ASHKEN IAN G H	Director	Nov 11 '24	Sale	36.98	46,457	1,717,980	5,632,322	Nov 13 06:50 PM
James E. Lillie	Director	Nov 11 '24	Proposed Sale	37.15	250,000	9,287,500		Nov 12 10:13 AM
Ian G. H. Ashken	Director	Nov 11 '24	Proposed Sale	37.15	200,000	7,430,000		Nov 12 09:55 AM
FRANKLIN MARTIN E	Director	Nov 04 '24	Sale	35.61	460,322	16,392,066	13,646,580	Nov 06 04:22 PM
FRANKLIN MARTIN E	Director	Nov 05 '24	Sale	35.14	199,678	7,016,685	13,446,902	Nov 06 04:22 PM
MEF Holdings, LLLP	Shareholder	Nov 04 '24	Proposed Sale	35.43	660,000	23,383,075		Nov 04 04:39 PM

Open in Screener

FDMT

4D Molecular Therapeutics Inc

Oct 07 • 11:37AM ET

8.26

-0.14 -1.67 %

Healthcare • Biotechnology • USA • NASD

FDMT 4D Molecular Therapeutics Inc daily Stock Chart

Peers: VRTX REGN BIIB SRPT CRSP NTLA EDIT BLUE ARWR SGMO

| Held by: VTI IWM IWN IBB VXF SCHA VTWO IWC PRFZ VHT

Index	RUT	P/E	-	EPS (ttm)	-3.71	Insider Own	8.75%	Shs Outstand	46.70M	Perf Week	-4.95%
Market Cap	385.76M	Forward P/E	-	EPS next Y	-3.81	Insider Trans	-0.06%	Shs Float	42.62M	Perf Month	18.51%
Enterprise Value	115.61M	PEG	-	EPS next Q	-0.98	Inst Own	81.98%	Short Float	11.01%	Perf Quarter	86.88%
Income	-196.14M	P/S	12858.72	EPS this Y	-23.95%	Inst Trans	-6.78%	Short Ratio	4.09	Perf Half Y	211.70%
Sales	0.03M	P/B	0.92	EPS next Y	-3.07%	ROA	-35.87%	Short Interest	4.69M	Perf YTD	48.29%
Book/sh	9.01	P/C	1.32	EPS next 5Y	-9.91%	ROE	-38.87%	52W High	9.96 -17.07%	Perf Year	-20.12%
Cash/sh	6.28	P/FCF	-	EPS past 3/5Y	-5.06% -9.89%	ROIC	-44.76%	52W Low	2.23 269.57%	Perf 3Y	2.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-87.29% -64.94%	Gross Margin	-21503.03%	Volatility	5.57% 6.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3853.72	EPS Y/Y TTM	-35.74%	Oper. Margin	-667654.55%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.75	Sales Y/Y TTM	-	Profit Margin	-594375.76%	RSI (14)	61.52	Recom	1.70
Dividend Gr. 3/5Y	- -	Current Ratio	8.75	EPS Q/Q	-54.56%	SMA20	6.87%	Beta	2.92	Target Price	31.12
Payout	-	Debt/Eq	0.05	Sales Q/Q	200.00%	SMA50	20.57%	Rel Volume	0.31	Prev Close	8.40
Employees	227	LT Debt/Eq	0.04	Earnings	Aug 11 BMO	SMA200	68.97%	Avg Volume	1.15M	Price	8.26
IPO	Dec 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-34.74% -96.16%	Trades		Volume	129,500	Change	-1.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$40 → $15
Nov-21-24	Initiated	Morgan Stanley	Underweight	$8
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight	$459
Apr-15-24	Initiated	Barclays	Overweight	$45
Feb-07-24	Resumed	Goldman	Buy	$81
Oct-26-23	Initiated	RBC Capital Mkts	Outperform	$25
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$32
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform	$24
Jul-05-23	Initiated	Chardan Capital Markets	Buy	$30
Jan-30-23	Initiated	BMO Capital Markets	Outperform	$50
Nov-18-22	Initiated	H.C. Wainwright	Buy	$36
Nov-15-22	Upgrade	Goldman	Neutral → Buy	$12 → $68
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12
Jun-22-22	Initiated	Jefferies	Buy	$22
Jan-04-22	Initiated	SVB Leerink	Outperform	$30
Jan-05-21	Initiated	Goldman	Neutral	$44
Jan-05-21	Initiated	Evercore ISI	Outperform	$70
Jan-05-21	Initiated	BofA Securities	Buy	$47

Show Previous Ratings

Sep-12-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Sep-11-25 12:45PM	SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag (Zacks)
Sep-05-25 03:12AM	Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec" (Insider Monkey) +9.98%
Sep-02-25 08:20PM	Lightning Round: Now is time to take a little off the table with Applovin, says Jim Cramer (CNBC TV) +5.37%
08:00AM	4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness (GlobeNewswire)
08:00AM	Loading…
Aug-25-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +11.21%
08:00AM	4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Aug-06-25 08:00AM	4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
Jul-31-25 04:05PM	4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update (GlobeNewswire) +42.67%
Jul-28-25 07:21AM	AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 \| Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies (GlobeNewswire)
Jul-24-25 08:00AM	4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists (GlobeNewswire)
Jul-21-25 08:00AM	BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer (Business Wire)
Jul-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
04:05PM	Loading…
Jul-02-25 04:05PM	4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution (GlobeNewswire)
May-28-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +7.50% +10.47%
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
May-05-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-02-25 06:51AM	FDA awards RMAT status to 4DMT diabetic macular oedema therapy (Pharmaceutical Technology) +9.30%
May-01-25 08:00AM	4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME (GlobeNewswire)
Apr-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +5.70%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -7.43%
Mar-27-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-10-25 08:00AM	4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD (GlobeNewswire)
Mar-04-25 08:05AM	4D Molecular price target lowered to $35 from $39 at RBC Capital (TipRanks)
Feb-28-25 04:05PM	4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire) -8.61%
Feb-19-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
02:30PM	Loading…
Feb-08-25 02:30PM	4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program (GlobeNewswire)
Jan-29-25 08:00AM	4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population (GlobeNewswire) +7.53%
Jan-10-25 08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD and DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire) -5.48%
08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire)
08:00AM	4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path (GlobeNewswire)
Dec-16-24 08:00AM	4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS (GlobeNewswire)
Nov-26-24 06:51AM	4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-14-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV (GlobeNewswire)
Nov-13-24 05:20PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Sep-25-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-23-24 08:00AM	4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-19-24 02:34PM	4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate (Benzinga) -19.74%
10:30AM	4D Molecular data bode well for eye gene therapy, but shares fall (BioPharma Dive)
Sep-18-24 04:05PM	4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day (GlobeNewswire)
Sep-05-24 08:00AM	4DMT Announces Presentations at Upcoming Retina Conferences (GlobeNewswire)
Sep-03-24 08:00AM	4DMT to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-27-24 08:00AM	4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 (GlobeNewswire)
Aug-23-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-12-24 08:00AM	4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-08-24 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Aug-05-24 08:00AM	4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board (GlobeNewswire) -5.97%
Jul-17-24 05:00AM	4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity (GlobeNewswire) -31.96%
Jul-12-24 09:40AM	4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last? (Zacks) +5.54%
Jul-08-24 05:52PM	4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock? (Insider Monkey) +5.58%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 08:00AM	4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy (GlobeNewswire)
Jun-18-24 08:00AM	4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast (GlobeNewswire)
Jun-08-24 04:30PM	4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-06-24 07:30AM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference (GlobeNewswire) -17.27%
Jun-04-24 08:00AM	4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-03-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-30-24 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47 European Cystic Fibrosis Conference (GlobeNewswire)
May-10-24 01:48PM	4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections (GuruFocus.com)
May-09-24 11:55PM	FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	4DMT Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
May-07-24 08:00AM	4DMT to Participate in Upcoming Investor Conference (GlobeNewswire)
May-01-24 10:01AM	4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +6.10%
08:00AM	4DMT Announces Presentations at ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 01:30AM	4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares (GuruFocus.com)
Mar-29-24 07:01PM	4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares (GuruFocus.com)
Mar-28-24 08:00AM	4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis (GlobeNewswire) -11.18%
Mar-04-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-02-24 04:32AM	4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 06:05PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4DMT Reports Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
Feb-12-24 08:00AM	4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium 2024 (GlobeNewswire)
Feb-08-24 03:05AM	Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc (GuruFocus.com)
Feb-06-24 11:27PM	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -14.97%
Feb-05-24 04:05PM	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +84.62%
02:50PM	Why Is 4D Molecular (FDMT) Stock Up 85% Today? (InvestorPlace)
12:36PM	4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' (Reuters)
Feb-03-24 05:00PM	4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD (GlobeNewswire)
Jan-29-24 08:00AM	4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden (GlobeNewswire)
Jan-25-24 10:04PM	4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares (GuruFocus.com) -8.28%
Jan-23-24 08:00AM	4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease (GlobeNewswire)
Jan-19-24 12:00PM	All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy (Zacks)
Jan-11-24 10:00AM	TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors (PR Newswire)
Jan-09-24 05:02AM	4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares (GuruFocus.com)
Jan-06-24 05:02AM	Andreas Halvorsen's Firm Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
05:02AM	Andreas Halvorsen Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
Jan-04-24 08:00AM	4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates (GlobeNewswire)
Jan-03-24 08:01AM	4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases (GlobeNewswire) -5.08%
Dec-21-23 08:00AM	4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD (GlobeNewswire) +7.35%
Dec-04-23 08:00AM	4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
Nov-15-23 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-09-23 04:19PM	4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire) +5.24%
Nov-01-23 04:00PM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC (GlobeNewswire)
Oct-30-23 08:00AM	4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy (GlobeNewswire)

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bizily Scott	Chief Legal Officer	Sep 23 '25	Sale	8.00	2,407	19,256	7,596	Sep 26 09:50 PM
SCOTT BIZILY	Officer	Sep 23 '25	Proposed Sale	7.40	7,312	54,109		Sep 23 04:20 PM

BBIO

BridgeBio Pharma Inc

APG

APi Group Corporation

FDMT

4D Molecular Therapeutics Inc

Upgrade your FINVIZ experience